NeuroVive Pharmaceutical AB Interim Report January – June 2019

On August 21, 2019 NeuroVive Pharmaceutical reported that Interim Report January – June 2019 (Press release, NeuroVive Pharmaceutical, AUG 21, 2019, View Source;june-2019-300904966.html [SID1234538923]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Important events April – June

The US Food and Drug Administration, FDA, approves NeuroVive’s IND (Investigational New Drug) application, enabling clinical studies in the US with the company’s drug candidate NeuroSTAT.
The Supreme Court delivers its ruling concerning arbitration between NeuroVive and CicloMulsion AG. The Supreme Court rejects NeuroVive’s appeal.
Annual General Meeting in NeuroVive was held on 25 April in Lund.
Important events after the reporting period

NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study.
NeuroSTAT has received Fast Track designation from the US Food and Drug Administration, FDA, facilitating its clinical development and path forwards to market.
Financial information Second quarter (April-June 2019)

Net revenues: KSEK 85 (0)
Other operating income: KSEK 1 000 (1 278)
Loss before tax: KSEK -20,769 (-25,481)
Loss per share*: SEK -0,14 (-0,40)
Diluted loss per share**: SEK -0,14 (-0,40)
Financial information First six months (January-June 2019)

Net revenues: KSEK 85 (0)
Other operating income: KSEK 1,000 (1,452)
Loss before tax: KSEK -34,591 (-38,534)
Loss per share*: SEK -0,23 (-0,61)
Diluted loss per share**: SEK -0,23 (-0,61)
* Profit/loss for the period divided by average number of shares before dilution at the end of the period.
** Profit/loss for the period divided by average number of shares after dilution at the end of the period.

Please find the complete interim report attached, or through our website www.neurovive.com.

The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CEST on 21 August 2019.